Introduction
============

Breast cancer is currently the most common malignancy diagnosed in women and is associated with the second-highest mortality rates, after lung cancer. In 2016, there were 246,660 confirmed diagnoses of breast cancer and an estimated 40,450 deaths attributed to the disease.[@b1-cmar-10-1015] Approximately 12.4% of women will be diagnosed with breast cancer in their lifetime and,[@b2-cmar-10-1015] though the malignancy is diagnosed at an early stage in 90% of patients, most tumors will progress to advanced or metastatic disease.[@b3-cmar-10-1015],[@b4-cmar-10-1015] Progression to metastatic breast cancer (MBC) is associated with median survival times of 18--24 months, and only 5% of patients are anticipated to be disease-free and alive at 5 years following tumor metastasis.[@b5-cmar-10-1015] Approximately 30%--40% of women diagnosed with invasive breast cancer will eventually develop MBC;[@b6-cmar-10-1015] in the USA, the 5-year survival rate for women with MBC is about 26%.[@b1-cmar-10-1015]

The most common neoplasms of the breast, found in 74% of patients, are hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2−). This subset of breast cancer has the most favorable disease prognosis, as HR-negative tumors respond to therapy at a lower rate and HER2+ tumors are more aggressive.[@b7-cmar-10-1015] The standard of care for post-menopausal women with HR+/HER2− breast cancer is endocrine therapy (ET).[@b8-cmar-10-1015] The primary agents used are selective androgen receptor modulators, which include tamoxifen (TAM) and fulvestrant (FUL); and aromatase inhibitors, which include exemestane (EXE), letrozole (LET), and anastrozole (ANA).[@b9-cmar-10-1015] Despite the variety of available therapies, only 20%--40% of patients will respond to these agents and most will develop resistance during their course of therapy.[@b10-cmar-10-1015],[@b11-cmar-10-1015]

Management of resistance requires the use of drugs that target the resistance pathway and subsequently improve sensitivity to ET.[@b8-cmar-10-1015] Drugs approved by the US Food and Drug Administration for the treatment of HR+/HER2− advanced breast cancer in combination with aromatase inhibitors are the mammalian target of rapamycin (mTOR) inhibitor everolimus (EVE) and the cyclin-dependent kinase (CDK) 4/6 inhibitors abemaciclib, palbociclib (PALBO), and ribociclib (RIBO). EVE and PALBO have been shown to improve progression-free survival (PFS) compared to ET alone in first-and second-line randomized controlled trials (RCTs).[@b12-cmar-10-1015],[@b13-cmar-10-1015] RIBO, given as first-line (1L) therapy for post-menopausal women with HR+/HER2− advanced breast cancer in combination with LET, has demonstrated improvement in PFS compared with LET alone in a Phase III RCT.[@b14-cmar-10-1015]

While the above-mentioned clinical trials reported improvements in PFS, data on overall survival (OS) with the use of some drugs, such as PALBO and RIBO, are limited, and it is uncertain whether improved PFS correlates with benefits in OS. To evaluate the available evidence for PFS and OS across Phase II and III RCTs of patients with HR+/HER2− MBC, we conducted a systematic literature review (SLR). In addition, we conducted a targeted literature search to identify factors that may influence OS in HR+/HER2− MBC and underlie treatment patterns. We also examined efficacy and health-related quality of life (HRQoL) changes relative to the line of therapy in HR+/HER2− MBC to determine if any trends were present.

Methods
=======

SLR protocol
------------

An SLR was performed following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.[@b15-cmar-10-1015] The inclusion criteria for the literature search and the methods of analysis were specified in advance and documented in a protocol, details are provided in the following section.

SLR eligibility criteria
------------------------

The SLR included original reports of Phase II and III RCTs in adult women with HR+/HER2− MBC, written in English and published between January 2006 and January 2017. Trials that enrolled both HER2− and HER2+ patients were included if \>80% of the enrolled patients had HER2− disease, requiring that results were provided for the HER2− subgroup. The extracted outcome measures for efficacy included PFS or time-to-progression (TTP), and OS reported as either median survival (in months) or hazard ratios (HRs) vs. comparators. Publications reporting meta-analyses were also retained in the SLR for reference cross-checking.

Studies with fewer than 10 patients and those that lacked any of the measures of interest were excluded. No limitations were placed on therapies except that they must be systemic. Studies of surgical interventions, radiotherapy/chemoradiation, or adjuvant/neo-adjuvant therapies were excluded.

In cases of duplicate publications or conference abstracts reporting data from a study with an available manuscript, the most recent manuscript was prioritized unless an older manuscript or more recent abstract included data points that were missing in the later manuscript.

The targeted literature search also included a review of post hoc statistical analyses of factors influencing OS, non-randomized studies of treatment patterns, and studies reporting HRQoL in HR+/HER2− MBC. The search strategy was based on similar criteria as mentioned earlier; however, eligible study designs also included observational studies, retrospective chart reviews, and patient surveys, provided that data on outcomes of interest were reported.

Information sources
-------------------

Studies were identified based on searches of the Embase, Medline, Daily Medline, and Medline In-Process electronic databases, Cochrane Central Register of Controlled Trials, Cochrane Database of Reviews of Effect, and Cochrane Database of Systematic Reviews. Additionally, congress abstracts from the American Society of Clinical Oncology, European Society of Medical Oncology, European Breast Cancer Conference, and San Antonio Breast Cancer Symposium libraries were identified. The literature search was conducted in January 2017 and included studies from January 2006 up to the date of the search. The full search strategy is available in [Tables S1](#SD1-cmar-10-1015){ref-type="supplementary-material"}[](#SD2-cmar-10-1015){ref-type="supplementary-material"}--[S3](#SD3-cmar-10-1015){ref-type="supplementary-material"}.

Study selection
---------------

Following the database searches, two independent analysts reviewed and selected studies based on abstracts and titles. The eligibility of abstracts and full-text articles was then independently assessed by the two reviewers in a standardized manner. Discrepancies were resolved by consensus between both reviewers.

Data collection process
-----------------------

A data extraction sheet was developed to tabulate the studies' characteristics (detailed below). One reviewer extracted the data and a second checked the extracted data for accuracy. As above, discrepancies were resolved by consensus between the two reviewers.

Data items
----------

The following data elements were extracted from each study: 1) trial characteristics included reference, name of trial, study design, phase of study, line of therapy (1L or second and later \[2L+\]), study interventions, class of intervention drug, and treatment arms; 2) population characteristics included total number of randomized participants, median age, number of patients with Eastern Cooperative Oncology Group performance status of 0 and 1, number of HER2− patients, number of HR+ patients, number of PR+ patients, endocrine status (resistant, sensitive, or mixed), number of premenopausal participants, number of patients with visceral metastases, number of patients with 1, 2, or ≥3 metastatic sites, number of patients with prior ET, and number of patients with prior adjuvant/neo-adjuvant/metastatic-setting chemotherapy; 3) trial outcomes included type of primary endpoint, whether PFS/TTP and/or OS were reported, PFS/TTP and OS results (median months of survival, HRs, confidence intervals, and *p*-values).

For the targeted literature search, additional data elements extracted included any HRQoL outcomes, patient burden (humanistic), number of lines of therapies including duration, sequence and efficacy in each line, and factors associated with OS.

Results
=======

Study selection
---------------

The database search returned 1017 records (Embase: 501, Cochrane: 272, Medline: 244). Of these, 636 were excluded due to failure to meet the inclusion criteria of population, intervention, outcomes, or study design. A further 274 duplicates were excluded, leaving a total of 107 full-text articles that were extracted and included in this SLR, 79 of which represent unique studies (58 1L, 21 2L+; [Figure 1](#f1-cmar-10-1015){ref-type="fig"}). The remaining 28 articles presented updated or interim data, the results of subgroup analyses, or were meta-analyses.

Study characteristics
---------------------

The breakdown of study treatments included in this SLR is presented in [Table 1](#t1-cmar-10-1015){ref-type="table"} and [Figure 2](#f2-cmar-10-1015){ref-type="fig"}. In total, 58 1L studies and 21 2L+ studies were included. PFS HR data were reported in 61 of the 79 unique studies (77%); of these, 31 (51%) reported significant PFS improvements. OS HR data were reported in 44 of the 79 studies (56%); of these, only 12 (27%) reported a significant OS improvement. Significant improvements in both PFS and OS were reported in only 6 (8%) studies (1 Phase II; 5 Phase III).

PFS
---

More Phase III than Phase II (15 vs. 4) RCTs reported statistically significant improvements in PFS in 1L therapy. Among the 19 1L studies that reported significant PFS improvement, 9 were of tyrosine kinase inhibitors (TKI) plus chemotherapy (CHEMO) and 3 were of CDK 4/6 inhibitor plus ET treatments.

We further evaluated PFS among RCTs that included ET as a control arm. Here, the greatest difference in PFS among arms was seen with the addition of a CDK4/6 inhibitor (PALBO or RIBO) to LET (HRs of 0.49 and 0.56, respectively) or mTOR inhibitor (EVE) to either EXE or TAM (HRs of 0.45 and 0.54, respectively). Of these, the PALBO+LET and EVE+TAM trials were 1L studies, while EVE+EXE included mostly 2L+ patients.[@b13-cmar-10-1015]--[@b15-cmar-10-1015] Statistically significant improvements in PFS were also seen with the addition of bevacizumab (BEV) to LET vs. LET alone (HR =0.75) and BEV to LET or FUL (vs. either LET or FUL, HR =0.83).[@b16-cmar-10-1015],[@b17-cmar-10-1015] Although the addition of ANA to FUL (vs. FUL alone) led to significant improvements in PFS (HR =0.80) in one study, this finding was not supported by another study (ANA+FUL vs. placebo + FUL, HR =1.0; [Figure 3](#f3-cmar-10-1015){ref-type="fig"}).[@b17-cmar-10-1015]

Overall survival
----------------

Among the 79 RCTs, 46 (58%) reported incremental OS months, and 44 (56%) presented HRs for OS. However, only 12 studies (15%) reported statistically significant improvements in OS: 9 were 1L and 3 were 2L+.

Six Phase III RCTs reported statistically significant improvements in OS in 1L therapy compared to 3 Phase II trials. Among the 9 1L studies that reported significant OS improvement, 3 were of ET and 2 were of TKI+CHEMO treatments.

Among RCTs with ET as a control arm, only 1 of 9 studies reported statistically significant improvements in OS. The addition of EVE to TAM (vs. TAM alone) yielded a 55% reduction in risk of death, though this was reported in a small (n=111) Phase II study of patients receiving 1L therapy.[@b16-cmar-10-1015] The addition of PALBO to LET vs. LET led to a 19% risk reduction (HR=0.81).[@b13-cmar-10-1015] In 2 RCTs, the addition of ANA to FUL yielded HRs of 0.81 and 0.95, respectively.[@b18-cmar-10-1015],[@b19-cmar-10-1015] The addition of BEV to either LET or LET+FUL did not yield consistent results with HRs of 0.87 and 1.13,[@b20-cmar-10-1015],[@b17-cmar-10-1015] respectively ([Figure 4](#f4-cmar-10-1015){ref-type="fig"}).

PFS and OS by study phase and line of therapy
---------------------------------------------

Among the 79 unique RCTs, only 6 studies (8%) reported statistically significant differences in both PFS and OS. Among these studies, the majority (5) were investigations of 1L therapies, and Phase III RCTs (also 5). Among 4 Phase III 1L studies that reported statistical significance in PFS and OS, 2 were of TKI+CHEMO, 1 of TKI+ET, and 1 of ET combination.

Factors influencing overall survival
------------------------------------

Multiple studies conducted subgroup analyses to identify clinical factors with an impact on OS. Park et al reported that median PFS of at least 7.6 months was associated with significantly longer OS (HR=0.34, confidence intervals: 0.25:0.46, *p*\<0.001).[@b21-cmar-10-1015] This and other studies also reported that demographic factors, baseline characteristics, prior adjuvant/neoadjuvant therapy as well as post-progression therapy, and the total number of lines of therapy have significant impact on final OS.[@b22-cmar-10-1015]--[@b30-cmar-10-1015]

Although RCTs can balance study populations on baseline characteristics and prior therapies, post-progression therapies or metastases cannot be controlled for in 1L studies. Factors demonstrated to affect OS are summarized in [Table 2](#t2-cmar-10-1015){ref-type="table"}.

Treatment patterns and HRQoL
----------------------------

Our targeted search found significant variability in the treatments used for 1L and 2L+ therapies, with no preferred treatment pathway and many patients receiving up to 6 lines of therapy.[@b31-cmar-10-1015] The median length of PFS and response to treatment decreased with subsequent lines of therapy.[@b21-cmar-10-1015] Park et al further reported that median PFS of \>7.6 months in 1L treatment was an important predictor of longer PFS in 2L, and PFS of \>5.1 months in 2L was associated with longer PFS in 3L.[@b21-cmar-10-1015]

There were very limited data available on HRQoL associated with PFS. One abstract reported EuroQol 5 Dimensions (EQ-5D) data from a study of S1 (tegafur, gimeracil, and oteracil) vs. taxanes (paclitaxel or docetaxel), showing decline in EQ-5D scores from 1L therapy to post-progression (0.81 vs. 0.72). Additionally, a recent abstract presenting data from the MONALEESA-1 trial on RIBO and LET treatment in HR+/HER2− MBC reported that HRQoL declined post-progression.[@b32-cmar-10-1015]

Discussion
==========

OS, as a direct measurement of clinical benefit to a patient, has been a preferred measurement of efficacy in MBC RCTs. While no measurement can definitively gauge treatment efficacy, OS conforms to the standards of evidence-based medicine in that it is easily measured, and is considered unbiased and objective. However, our research has demonstrated that, overall, a minority of studies have reported significant OS improvements: among the 79 identified RCTs in HR+/HER2− MBC, only 12 reported improvements in OS. Besides the choice of treatment in 1L therapy, many factors influence OS. Multiple studies reported that patient demographics, baseline characteristics, prior adjuvant/neoadjuvant therapy as well as post-progression therapy, and the total number of lines of therapy have significant impacts on final OS. Though further removed from objectivity, PFS is commonly reported because it can be observed while respecting the time constraints that often impinge on clinical trials. Most importantly, PFS in 1L was documented as a significant factor in OS.[@b33-cmar-10-1015]

There is significant heterogeneity in MBC treatment, with many lines of therapies and no defined pathway. Macalalad et al documented variability in treatment patterns and over 5 lines of therapies among MBC patients.[@b31-cmar-10-1015] Kantar Health CancerMpact 2016 also reported on variability of treatment choices and observed that a significant proportion of patients who progress on a previous line of therapy subsequently utilize the next line of treatment for up to 6 lines.[@b34-cmar-10-1015] With the considerable variability in treatment patterns and many contributing factors to OS, there are concerns that the efficacy of 1L therapies measured by OS may be diluted or biased in clinical trials, thereby underestimating their true clinical benefit.

Both PFS and response rates decrease as MBC progresses. Park et al reported a decline in months of PFS and response rates by line of therapy among MBC patients.[@b21-cmar-10-1015] Quality of life also decreases from 1L therapy to post-progression, as reported by Fukuda et al.[@b32-cmar-10-1015] As such, improvement in PFS with maintained HRQoL may be a more suitable and robust endpoint in 1L RCTs of patients with HR+/HER2− MBC.

Conclusion
==========

The goal of treatment in MBC is to prolong life while maintaining the quality of survival. As such, RCTs of MBC treatments ideally measure OS and HRQoL. In clinical trials of 1L therapies, OS is affected by multiple factors that cannot be controlled. This study examined important characteristics of RCTs in MBC and their relevance to OS. In addition to demographics, baseline characteristics, and prior adjuvant/neoadjuvant therapy, final OS is influenced by post-progression therapy and the total number of lines of therapy. This SLR found that ultimately very few 1L RCTs report OS improvement. PFS improvement is more often reported and its significance is perhaps understated. PFS, response rates, and QoL decrease as the disease progresses and with each line of therapy. PFS in 1L is an important predictor of PFS in further lines of therapy. In 1L treatments for MBC, PFS improvement coupled with maintained HRQoL provides patients with more meaningful time and may be considered the best possible outcome.

Supplementary materials
=======================

Search strategy
---------------

###### 

Ovid Medline^®^ Epub ahead of print, in-process, and other non-indexed citations. Ovid Medline^®^ daily and Ovid Medline^®^ 1946 to present database

  ------------------------ ---------------------------------------------------------------------------- -----------
  **Date:** January 2017                                                                                
  1                        Exp breast neoplasms/                                                        250,773
  2                        (Breast adj6 cancer\$).af.                                                   246,948
  3                        (Breast adj6 neoplas\$).af.                                                  252,542
  4                        (breast adj6 carcinoma\$).af.                                                63,807
  5                        (Breast adj6 tumor\$).af.                                                    7401
  6                        (Breast adj6 tumor\$).af.                                                    48,416
  7                        1 or 2 or 3 or 4 or 5 or 6                                                   336,672
  8                        Metasta\$.mp. or exp neoplasm metastasis/                                    477,568
  9                        7 and 8                                                                      74,656
  10                       ("Metastatic breast cancer" or "metastatic breast neoplasms").af.            11,972
  11                       9 or 10                                                                      74,661
  12                       "Hormone receptor positive".af.                                              2300
  13                       "Hormone receptor-positive".af.                                              2300
  14                       ("Estrogen receptor-positive" or "oestrogen receptor-positive").af.          4218
  15                       "Progesterone receptor-positive".af.                                         732
  16                       "Hormone sensitive".af.                                                      3719
  17                       12 or 13 or 14 or 15 or 16                                                   10,513
  18                       11 and 17                                                                    1955
  19                       Exp randomized controlled trials/                                            111,704
  20                       Randomized controlled trial.pt.                                              448,501
  21                       Exp random allocation/or exp randomization/                                  89,826
  22                       Exp placebos/                                                                34,191
  23                       Exp double-blind method/or double-blind\$.af.                                180,225
  24                       Exp multicenter study/or Multicent\$.af.                                     279,405
  25                       Random\$.ti,ab,kw,sh.                                                        1,124,651
  26                       Blind\$.ti,ab,kw,sh.                                                         263,750
  27                       Placebo\$.ti,ab,kw,sh.                                                       203,823
  28                       Parallel\$.ti,ab,kw,sh.                                                      266,233
  29                       Exp clinical trial, phase 3/                                                 13,116
  30                       Exp clinical trial, phase 2/                                                 29,002
  31                       ("Phase III" or "phase 2" or ("phase III" or "phase II")).af.                112,861
  32                       19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31   1,752,319
  33                       18 and 32                                                                    610
  34                       Limit 33 to yr="2006--Current"                                               422
  35                       Limit 34 to "review articles"                                                74
  36                       34 not 35                                                                    348
  37                       Limit 36 to humans                                                           297
  38                       Remove duplicates from 37                                                    **244**
  ------------------------ ---------------------------------------------------------------------------- -----------

**Notes:** Bold font indicates the total number of articles collect in each search.

###### 

EBM Reviews, Cochrane Database of Systematic Reviews 2005 to June 9, 2017; Database Info Icon EBM Reviews, ACP Journal Club 1991 to May 2017; Database Info Icon EBM Reviews, Database of Abstracts of Reviews of Effects 1st Quarter 2016; Database Info Icon EBM Reviews, Cochrane Central Register of Controlled Trials April 2017; Database Info Icon EBM Reviews, Cochrane Methodology Register 3rd Quarter 2012; Database Info Icon EBM Reviews, Health Technology Assessment 4th Quarter 2016; Database Info Icon EBM Reviews, NHS Economic Evaluation Database 1st Quarter 2016

  ------------------------ ------------------------------------------------------------------ ---------
  **Date:** January 2017                                                                      
  1                        Exp breast neoplasms                                               9184
  2                        Breast adj6 cancer\$                                               21,934
  3                        Breast adj6 neoplas\$                                              10,989
  4                        Breast adj6 carcinoma\$                                            2112
  5                        Breast adj6 tumor\$                                                573
  6                        Breast adj6 tumor\$                                                1851
  7                        1 or 2 or 3 or 4 or 5 or 6                                         23,744
  8                        Metasta\$                                                          21,265
  9                        Neoplasm Metastasis.sh.                                            2226
  10                       8 or 9                                                             21,265
  11                       7 and 10                                                           6121
  12                       "Hormone receptor positive"                                        607
  13                       Hormone receptor-positive' 588                                     607
  14                       Estrogen receptor-positive' or "oestrogen receptor-positive" 654   522
  15                       "Progesterone receptor-positive" 250                               109
  16                       Hormone sensitive 986                                              210
  17                       12 or 13 or 14 or 15 or 16 2325                                    1318
  18                       11 and 17                                                          453
  19                       Limit 18 to yr="2006--Current"                                     329
  20                       Limit 19 to english language                                       284
  21                       Limit 20 to humans                                                 278
  22                       Remove duplicates from 21                                          **272**
  ------------------------ ------------------------------------------------------------------ ---------

**Notes:** Bold font indicates the total number of articles collect in each search.

###### 

Embase database 1974 to 2017 June 09

  ------------------------ -------------------------------------------------------------------------------------------------- -----------
  **Date**: January 2017                                                                                                      
  1                        Breast cancer'.af.                                                                                 404,912
  2                        Exp breast tumor/                                                                                  456,726
  3                        (Breast adj6 tumor^\*^).mp                                                                         10,358
  4                        (Breast adj6 tumor^\*^).mp                                                                         132,238
  5                        (Breast adj6 neoplas^\*^).mp                                                                       22,949
  6                        (Breast adj6 cancer^\*^).mp                                                                        446,177
  7                        (Breast adj6 carcinoma^\*^).mp                                                                     95,202
  8                        1 or 2 or 3 or 4 or 5 or 6 or 7                                                                    513,111
  9                        Metastasis/                                                                                        310,169
  10                       Metasta\*                                                                                          697,570
  11                       9 or 10                                                                                            697,570
  12                       8 and 11                                                                                           123,533
  13                       ("metastatic breast neoplasms" or "metastatic breast neoplasm" or "metastatic breast cancer").mp   19,097
  14                       12 or 13                                                                                           123,533
  15                       Hormone receptor positive' OR "hormone receptor-positive"                                          3917
  16                       Progesterone receptor-positive' OR "progesterone receptor positive"                                1185
  17                       Estrogen receptor-positive' or "oestrogen receptor-positive"                                       7549
  18                       Hormone sensitive'                                                                                 4924
  19                       Hormone adj3 positive                                                                              5460
  20                       15 or 16 or 17 or 18 or 19                                                                         17,999
  21                       14 and 20                                                                                          4258
  22                       Exp "randomized controlled trial"/                                                                 481,221
  23                       Randomization/                                                                                     84,943
  24                       Random^\*^.ti,ab.                                                                                  1,181,594
  25                       Parallel^\*^.ti,ab                                                                                 303,245
  26                       (\[Single or double or triple\] adj3 \[blind^\*^ or mask^\*^ or dummy\]).ti,ab.                    201,720
  27                       Double-blind' or "double-blinded"                                                                  219,339
  28                       Multicenter study' or multicent^\*^                                                                277,968
  29                       Blind^\*^.ti,ab.                                                                                   341,487
  30                       Placebo^\*^.ti,ab                                                                                  254,042
  31                       ("Phase III" OR "phase II").ti,ab                                                                  40,098
  32                       ("Phase III" OR "phase II").ti,ab                                                                  111,214
  33                       22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32                                     2,028,041
  34                       21 and 33                                                                                          1173
  35                       Limit 34 to human                                                                                  1094
  36                       Limit 35 to english language                                                                       1075
  37                       Limit 36 to yr="2006 -Current"                                                                     898
  38                       Limit 37 to embase                                                                                 562
  39                       Limit 38 to (article or conference abstract)                                                       **501**
  ------------------------ -------------------------------------------------------------------------------------------------- -----------

**Notes:** Bold font indicates the total number of articles collect in each search.
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###### 

Systematic literature review results according to OS and PFS reporting

  N                                  All studies   First-line studies   Second-line studies and beyond
  ---------------------------------- ------------- -------------------- --------------------------------
  Reported PFS months                67            47                   20
  Reported PFS hazard ratio          61            45                   16
  Reported significant PFS           31            19                   12
  Reported OS months                 46            35                   11
  Reported OS hazard ratio           44            27                   17
  Reported significant OS            12            9                    3
  Reported PFS and OS months         39            29                   10
  Reported PFS and OS hazard ratio   40            31                   9
  Reported significant PFS and OS    6             5                    1
  Total unique studies               79            58                   21

**Abbreviations:** OS, overall survival; PFS, progression-free survival.

###### 

Factors impacting OS in MBC

  ---------------------------------------------------------------------------------------------------------------------------
  Demographics    Disease characteristics       Prior therapy                             Post-progression therapy
  --------------- ----------------------------- ----------------------------------------- -----------------------------------
  Age ≥65 years   Measurable disease            Prior endocrine therapy                   Type of post-progression

  Region          ECOG (1--2 vs. 0)\            Prior chemotherapy (adjust/neoadjuvant)   Lines of post-progression therapy
                  Number of organs involved\                                              
                  Number of metastatic sites\                                             
                  Visceral involvement\                                                   
                  CNS metastases\                                                         
                  Liver metastases\                                                       
                  Disease-free interval                                                   
  ---------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; MBC, metastatic breast cancer, OS, overall survival.
